Has Natera (NTRA) Left Enough Upside In Its Cash Flow Story?

Natera has seen its stock price race ahead in recent years, while fresh clinical data and product wins keep reshaping expectations for its business. With the share price now reflecting a long list of oncology and genetics ambitions, the question is how fully those hopes are backed by the cash flows the company can generate.

• Over the past 3 years, Natera has delivered a very large share price gain of about 7x, which puts a lot of emphasis on whether its current valuation is grounded in the cash its tests can produce.
• New evidence and expanded coverage for the Signatera minimal residual disease and immunotherapy monitoring platform can support expectations for future testing volumes and may influence when the business turns its clinical traction into sustained cash generation.
• What if you looked at Natera through its sales instead? See why Natera's 19.4x P/S tells a different valuation story.

The stock's next move may depend on whether the cash flows implied by Natera's current price look consistent with its Discounted Cash Flow (DCF) based intrinsic value estimate.

If you want to stress test this same cash flow question beyond Natera, apply the same analysis to 42 high quality undervalued stocks.

Does Natera Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash Natera can return to shareholders over time and discounts it back to today. On that score, the latest twelve month free cash flow sits at about $84.3 million, while the projections used in the model assume that future free cash flow grows materially from this base rather than declining or staying flat.

Those forecasts imply a business that leans heavily on expanding testing volumes and improving profitability, which ties directly to areas like the Signatera oncology platform and broader genetics portfolio. Because the DCF outcome sits substantially above the current share price of $363.76, the market is treating those long range cash flows as relatively uncertain. The recently raised 2026 revenue guidance and leadership change to a new CEO help explain why the valuation model and share price can point in different directions at the moment, since investors still need to see how that growth translates into durable free cash generation. Find out what Natera could be worth using our Discounted Cash Flow (DCF) estimate.

The Natera Narrative: What Would Justify Today's Price?

Natera Narratives pick up where the DCF puzzle leaves off and spell out which combinations of growth, margins and future earnings would need to hold for the stock to be worth materially more or less than today. Each scenario ties a fair value estimate to a specific set of potential catalysts and risks for Natera's business, so you can track over time which version of events appears to be unfolding in the real world.

Community views on Natera are split between those who see the MRD and genetics engine as underappreciated and those who think reimbursement and spending risks already loom large.

Bull case: 13% undervalued

"Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection..."

Discover why this Narrative puts Natera at 13% undervalued.

Bear case: 30% overvalued

"Bearish analysts expect Natera’s heavier capital expenditure on early detection projects and large-scale lab build-out to keep regulatory and reimbursement risks around certain tests, including potential cuts for NIPT, firmly in focus as a threat to revenue quality and pricing power..."

Explore why this Narrative puts Natera at 30% overvalued.

Natera’s price is one question, who is steering it is another

Before making any call on Natera, it helps to understand who is actually driving the decisions and how their incentives line up with long term shareholders. See who runs Natera and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com